Breckenridge Pharmaceutical, Inc. Announces Appointment of New President

BOCA RATON, Fla., Nov. 20, 2014 /PRNewswire/ -- Breckenridge Pharmaceutical, Inc. announced the appointment of Larry Lapila to the position of President. Lapila previously served as Executive Vice President and has been with the company since 2001.

Lapila succeeds Laurence D. (Larry) Runsdorf, who recently left his role as President and CEO, a role he filled since founding the company in 1983.  Mr. Runsdorf will continue to work with the company on expansion strategies, and will remain on its Board of Directors. 

About Breckenridge:
Breckenridge Pharmaceutical, Inc. is a privately-held pharmaceutical marketing, research and development company founded in 1983 that markets a broad range of generic prescription products in many therapeutic categories.  The Breckenridge label is recognized by Wholesalers, Distributors, Chains, and Managed Care Accounts, as well as Retail Pharmacies nationwide.  Breckenridge markets in excess of fifty (50) products in a variety of dosage forms and therapeutic categories.

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.